Sales in Asia Pacific are derived from Mylan's operations in India, Australia, Japan and New Zealand. Asia Pacific third party net sales were $310.6 million for the current quarter, compared to $267.9 million for the comparable prior year period, an increase of $42.7 million, or 15.9%. Foreign currency translation had a positive impact on sales for the current quarter, reflecting the strengthening of certain regional currencies against the U.S. Dollar. Excluding the effect of foreign currency, calculated as described above, the increase was approximately $23 million, or 8%. This increase is primarily driven by higher third party sales from India, with growth in third party sales in Japan also contributing.
For the current quarter, the Specialty segment reported third party net sales of $213.9 million, an increase of $72.8 million, or 51.6%, from the comparable prior year period of $141.1 million. The increase was the result of higher sales of the EpiPen® Auto-Injector, which is used in the treatment of severe allergic reactions, and Dey's Perforomist® Inhalation Solution. The increased sales of the EpiPen® Auto-Injector were the result of favorable pricing and volume, both in the U.S. and worldwide, while the increased sales of the Perforomist® Inhalation Solution were the result of increased volume.
Gross profit for the three months ended September 30, 2011 was $658.4 million and gross margins were 41.8%. For the three months ended September 30, 2010, gross profit was $580.1 million, and gross margins were 42.8%. Gross profit for the current quarter is impacted by certain purchase accounting related items, of approximately $104.1 million, which consisted primar
|SOURCE Mylan Inc.|
Copyright©2010 PR Newswire.
All rights reserved